ABSTRACT
<b>Introduction</b>: Dermatological disorders are one of the adverse events caused by cancer chemotherapy and are a dose-limiting factor for some anti-neoplastic agents. The severe symptoms associated with these disorders affect the patients’ quality of life (QOL). Early countermeasures for the onset of dermatological disorders associated with anti-neoplastic agent administration might be important.<br><b>Materials and Methods: </b>We analyzed the occurrences of dermatological disorders after administration of an anti-neoplastic agent in the Food and Drug Administration Adverse Event Reporting System (FAERS), and compared the adverse event (AE) reporting ratio of the total reports. In addition, we studied the association between anti-neoplastic agents and dermatological disorders using cluster analysis. Reports for 15 anti-neoplastic agents (4 anti-neoplastic agents and 11 molecular target drugs) were analyzed.<br><b>Results: </b>After excluding duplicate data in FAERS, 6,157,897 reports were analyzed. The number of reports that showed a dermatological disorder was 534,934. The reporting ratio of hand-foot syndrome with sorafenib and capecitabine was 11.20% and 7.05%, respectively.<br><b>Conclusions: </b>We set the cluster number at six; cluster features obtained were as follows: (1) the reporting ratio of hand-foot syndrome was especially high, followed by the reporting ratio of rash, (2) the reporting ratio of rash and erythema was high. Similar anti-neoplastic agents may demonstrate similar occurrence tendencies of AEs and cluster features. Further studies are required to draw conclusions over these findings. Information services based on the feature of each cluster might be useful to improve patient QOL at the clinical site.
ABSTRACT
<b>Introduction</b>: It is said that molecular target agents are more durable than cytotoxicic ones, although they have their own specific side effects. We experienced a case of non-small cell lung cancer with leptomeningeal metastasis and she had molecular target agents, she had palliation of symptom and prolongation of survival time. <b>Case</b>: Patient is 76 years old Japanese woman without smoking history. In April 2010 speech and gate disturbance was appeared on her, she was examined by CT and MRI, these revealed lung cancer, intrapulmonary metastasis, lymph nodal involvement, leptomeningeal metastasis, brain metastasis, and spinal bone metastasis in vertebras (T1bN1M1b, Stage IV). Symptoms such as gate disturbance, decrease of oral intake, drowsiness was regression rapidly, so patient and family decided discharge to go to home. She started to take elrotinib 100 mg on yth May. at home. She took elrotinib 150 mg since 6th June 2010 until July 2011 on her death. 2 weeks after administration of elrotinib she came to be able to eat and get up. On 6th August 2010 after administration of elrotinib primary lesion of lung cancer showed PR by CT, leptomeningeal and brain metastases showed SD by MRI. Grade 2 of skin rashu was manageable with topical corticosteroids. The remaining days from a diagnosis of the metastasis to lung cancer with leptomeningeal metastasis are reported with around three months. A symptom was relieved by the dosage of erlotinib,and there was not a serious side effect, and the patient could survive for one year and 5 months.